Tasly Pharmaceutical Group Co Ltd

Tasly maintains a strong liquidity position with a current ratio of 3.57, indicating the company can cover its short-term obligations more than three times over. The company's liquidity_fpt is supported by a free cash flow of 502.03 million CNY, though its capital expenditure of -381.26 million CNY suggests ongoing investment in operations. The debt-to-equity ratio of 0.12 reflects a conservative capital structure, with long-term debt of 1.44 billion CNY compared to total equity of 12.4 billion CNY. Profitability metrics show Tasly's return on equity of 8.91% and return on assets of 7.2%, both above the industry median for pharmaceutical firms. The company's net income of 1.1 billion CNY and operating income of 1.35 billion CNY indicate strong operational performance. Gross profit of 5.49 billion CNY on revenue of 8.24 billion CNY suggests a healthy margin profile, though the exact industry median for gross margin is not provided in the input data. Tasly's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's financial snapshot does not provide segment-level revenue breakdowns, but the absence of multiple business lines suggests a high degree of concentration in its pharmaceutical operations. This lack of diversification could expose the company to sector-specific risks, such as regulatory changes or patent expirations. Looking ahead, Tasly's revenue is expected to grow, though the exact numeric delta is not provided in the input data. Analysts have assigned a mean price target of 16.61 CNY and a median of 16.97 CNY, with a mean recommendation of 1.57 (leaning toward strong buy). The company's free cash flow and operating cash flow of 502.03 million CNY and 1.42 billion CNY, respectively, support its ability to sustain operations and fund growth initiatives. The risk assessment highlights a medium liquidity risk, primarily due to negative net cash after subtracting total debt. While the company's debt-to-equity ratio is low, the risk of dilution is assessed as low, with no immediate pressure from share issuance or ATM programs. The absence of disclosed dilution sources in the input data supports this low-risk rating, though the company's capital structure should be monitored for future changes. Recent events include analyst estimates and price targets, with four strong-buy ratings and two buy ratings. The company has not disclosed any recent filings or transcripts in the input data, so no specific events are available for analysis. Analysts' positive outlook is supported by Tasly's strong cash flow and profitability, but investors should remain cautious about the company's revenue concentration and potential regulatory risks in the pharmaceutical sector.